Related Experiment Video

Updated: Mar 30, 2026

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
07:15

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation

Published on: January 16, 2019

11.5K

Genetics of channelopathies associated with sudden cardiac death

Oscar Campuzano1, Georgia Sarquella-Brugada2, Ramon Brugada1

  • 1Cardiovascular Genetics Center, University of Girona - IDIBGI, Spain ; Department of Medical Sciences, School of Medicine, University of Girona, Spain.

Global Cardiology Science & Practice
|November 14, 2015
PubMed

Insights

Sudden cardiac death (SCD) is a challenge due to genetic heart conditions like channelopathies. Genetic testing is crucial for diagnosing SCD causes in patients and families, improving prevention strategies.

Area of Science:

  • Cardiology
  • Genetics
  • Molecular Biology

Background:

  • Sudden cardiac death (SCD) remains a significant clinical challenge, often linked to genetic heart diseases with variable expressivity.
  • Incomplete penetrance of genetic conditions means individuals may be unaware of their risk, with physical activity potentially triggering the first symptom, such as syncope.

Purpose of the Study:

  • This review focuses on recent advancements in understanding the genetics of channelopathies.
  • To highlight the role of genetic testing in diagnosing SCD, including in asymptomatic family members and unexplained post-mortem cases.

Main Methods:

  • Review of recent technological advances in cardiology and genetics.
  • Analysis of genetic testing applications in the field of sudden cardiac death.

Main Results:

  • Genetic testing has become integral to identifying the causes of SCD.
  • Channelopathies are a primary suspect in unexplained SCD cases.
  • Genetic insights aid in diagnosing affected individuals, asymptomatic relatives, and post-mortem cases.

Conclusions:

  • Technological progress in genetics offers improved diagnostic capabilities for SCD.
  • Understanding the genetic basis of channelopathies is key to preventing sudden cardiac death and managing at-risk families.

Keywords:
Sudden cardiac deatharrhythmiaschannelopathiesgenetics

More Related Videos

Determination of the Relative Cell Surface and Total Expression of Recombinant Ion Channels Using Flow Cytometry11:32

Determination of the Relative Cell Surface and Total Expression of Recombinant Ion Channels Using Flow Cytometry

Published on: September 28, 2016

14.0K
Implantation of Electroencephalogram and Electrocardiogram Telemetry Devices in Neonatal Rabbit Kits06:46

Implantation of Electroencephalogram and Electrocardiogram Telemetry Devices in Neonatal Rabbit Kits

Published on: February 28, 2025

896

Related Concept Videos

Mechanism of Cardiac Arrhythmias01:28

Mechanism of Cardiac Arrhythmias

Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
2.6K
Voltage-gated Ion Channels01:26

Voltage-gated Ion Channels

Voltage-gated ion channels are transmembrane proteins that open and close in response to changes in the membrane potential. They are present on the membranes of all electrically excitable cells such as neurons, heart, and muscle cells.
Generally, all voltage-gated ion channels have a 'voltage-sensing domain' that spans the lipid bilayer. The charged residues in the sensor move in response to the membrane potential changes that open the channel allowing ions movement. There are several types of...
13.1K
Voltage-gated Ion Channels01:26

Voltage-gated Ion Channels

6.4K
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
697
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
95
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
109